Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Certara Inc (CERT)

Certara Inc (CERT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,537,311
  • Shares Outstanding, K 160,975
  • Annual Sales, $ 354,340 K
  • Annual Income, $ -55,360 K
  • EBIT $ 36 M
  • EBITDA $ 140 M
  • 60-Month Beta 1.51
  • Price/Sales 4.49
  • Price/Cash Flow 10.44
  • Price/Book 1.51

Options Overview Details

View History
  • Implied Volatility 78.71% ( +19.84%)
  • Historical Volatility 37.58%
  • IV Percentile 62%
  • IV Rank 51.67%
  • IV High 141.52% on 11/12/24
  • IV Low 11.58% on 09/23/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 78
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 955
  • Open Int (30-Day) 1,470

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.10
  • Number of Estimates 4
  • High Estimate 0.13
  • Low Estimate 0.08
  • Prior Year 0.05
  • Growth Rate Est. (year over year) +100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.41 +3.83%
on 11/21/24
11.44 -14.60%
on 10/22/24
-1.43 (-12.77%)
since 10/21/24
3-Month
9.41 +3.83%
on 11/21/24
13.52 -27.74%
on 08/26/24
-3.13 (-24.26%)
since 08/21/24
52-Week
9.41 +3.83%
on 11/21/24
19.87 -50.83%
on 03/08/24
-4.65 (-32.25%)
since 11/21/23

Most Recent Stories

More News
Certara Reports Third Quarter 2024 Financial Results

CERT : 9.77 (+2.30%)
Certara to Participate in the Stephens Annual Investment Conference

CERT : 9.77 (+2.30%)
Certara Appoints John Reynders as New Independent Board Member

CERT : 9.77 (+2.30%)
MaxCyte Appoints Cynthia Collins to its Board of Directors

PSTX : 2.71 (-0.37%)
MXCN.LN : 680.000 (unch)
DMTKQ : 0.0001 (unch)
MXCT.LN : 266.000 (+1.53%)
MXCT : 3.45 (-1.15%)
CERT : 9.77 (+2.30%)
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024

CERT : 9.77 (+2.30%)
Cerrado Announces Clarification on Prior Agreements with Red Cloud, Feneck Consulting Group and Ascendant Resources

TORONTO, ON / ACCESSWIRE / August 2, 2024 / Cerrado Gold Inc. (TSX.V:CERT)(OTCQX:CRDOF) ("Cerrado" or the "Company"), at the request of the TSX Venture Exchange, announces previous engagements with Red...

CERT : 9.77 (+2.30%)
CRDOF : 0.2649 (-0.60%)
Are These 3 Small Momentum Stocks Setting Up Big Gains?

MINISO, PDF Solutions, and Certara are small stocks with strong price momentum. It’s not unusual for small stocks to show more price momentum than larger peers.

MNSO : 16.99 (-4.01%)
PDFS : 30.79 (+1.92%)
CERT : 9.77 (+2.30%)
RBA : 95.34 (+1.71%)
Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal

Xentria, Inc., a biotech company focused on developing treatments to address unmet clinical needs, today announced the peer reviewed publication in Frontiers in Pharmacology of a biosimulation model...

CERT : 9.77 (+2.30%)
Why Certara's Shares Rose 37.7% This Week

The company, which helps other companies in their drug development, reported strong third-quarter numbers.

CERT : 9.77 (+2.30%)
Certara, Inc. (CERT) Q2 2022 Earnings Call Transcript

CERT earnings call for the period ending June 30, 2022.

CERT : 9.77 (+2.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Certara Inc. provides medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Certara Inc. is based in NJ, United States.

See More

Key Turning Points

3rd Resistance Point 10.30
2nd Resistance Point 10.05
1st Resistance Point 9.91
Last Price 9.77
1st Support Level 9.52
2nd Support Level 9.27
3rd Support Level 9.13

See More

52-Week High 19.87
Fibonacci 61.8% 15.87
Fibonacci 50% 14.64
Fibonacci 38.2% 13.41
Last Price 9.77
52-Week Low 9.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar